ESMO Lifetime Achievement Award

The Dutch Cancer Institute (NKI) has won the ESMO Lifetime Achievement Award, presented by The European Society for Medical Oncology, for its `excellent translational research into breast cancer´.

Photo: ESMO Lifetime Achievement Award

The NKI has bridged the field of molecular biological research and the clinic. In particular it has developed genetic assays for breast cancer that, according to ESMO, lead to better understanding of the disease and probably to more precise and less aggressive treatment.
The ESMO award – which includes ?50,000 for research - was presented for the second time; last year it went to the Breast International Group (BIG), a platform for clinical research into breast cancer.

Apologies instead of condolences
The wife of a patient, who had been treated in the ICU of the Medisch Spectrum Twente Hospital after receiving serious burns during a barbecue accident, received a questionnaire asking her to tell the hospital management about her experience with condolences she had received. The hospital letter arrived just as her husband arrived home. Its opening sentence read: ‘Recently your husband died in the intensive care ward….’ The hospital offered its apologies … better than condolences!

31.08.2007

More on the subject:

Related articles

Photo

News • Orthopedic ultrasound screening

AI helps spot signs of dysplasia in infant hips

Developmental dysplasia of the hip occurs in 2-4% of infants, but screening via ultrasound is notoriously hard to master. An AI-assisted application could prevent many unnecessary hospital referrals.

Photo

News • Transition changes

How menopause restructures a woman’s brain

During menopause, many women experience forgetfulness, trouble concentrating, and mental fatigue. A new review explores the link between brain changes during menopause and these symptoms.

Photo

News • Proteins for personalized treatments

Tracking Duchenne muscular dystrophy with blood biomarkers

Newly discovered blood biomarkers may offer new options to track Duchenne muscular dystrophy (DMD) in a less invasive way than physical tests or biopsies. This could support more tailored treatments.

Related products

Subscribe to Newsletter